JP7078405B2 - カリケアマイシン誘導体およびその抗体薬物コンジュゲート - Google Patents

カリケアマイシン誘導体およびその抗体薬物コンジュゲート Download PDF

Info

Publication number
JP7078405B2
JP7078405B2 JP2018008065A JP2018008065A JP7078405B2 JP 7078405 B2 JP7078405 B2 JP 7078405B2 JP 2018008065 A JP2018008065 A JP 2018008065A JP 2018008065 A JP2018008065 A JP 2018008065A JP 7078405 B2 JP7078405 B2 JP 7078405B2
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
nrc
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018008065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018123122A (ja
JP2018123122A5 (https=
Inventor
カレード アハマッド オマール
ポール ブラウン ステファン
ジョン ディリコ ケネス
ダッシン ラッセル
フレデリック フィルツェン ゲイリー
パセンヴィーティル スジエット
ストラップ パーヴェル
サブラマンヤム チャクラパニー
エヌ．トゥミー ローレンス
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2018123122A publication Critical patent/JP2018123122A/ja
Publication of JP2018123122A5 publication Critical patent/JP2018123122A5/ja
Application granted granted Critical
Publication of JP7078405B2 publication Critical patent/JP7078405B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2018008065A 2017-01-24 2018-01-22 カリケアマイシン誘導体およびその抗体薬物コンジュゲート Active JP7078405B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449839P 2017-01-24 2017-01-24
US62/449839 2017-01-24

Publications (3)

Publication Number Publication Date
JP2018123122A JP2018123122A (ja) 2018-08-09
JP2018123122A5 JP2018123122A5 (https=) 2021-02-18
JP7078405B2 true JP7078405B2 (ja) 2022-05-31

Family

ID=61168135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018008065A Active JP7078405B2 (ja) 2017-01-24 2018-01-22 カリケアマイシン誘導体およびその抗体薬物コンジュゲート

Country Status (14)

Country Link
US (2) US11993625B2 (https=)
EP (1) EP3573995A1 (https=)
JP (1) JP7078405B2 (https=)
KR (1) KR20190111086A (https=)
CN (1) CN110461860A (https=)
AU (1) AU2018211561B2 (https=)
BR (1) BR112019015069A2 (https=)
CA (1) CA3051038C (https=)
IL (1) IL268245A (https=)
MX (1) MX2019008773A (https=)
RU (1) RU2732568C1 (https=)
SG (1) SG11201906414VA (https=)
TW (1) TWI687221B (https=)
WO (1) WO2018138591A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
MX2019008773A (es) * 2017-01-24 2019-09-18 Pfizer Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
EP3720504A1 (en) * 2017-12-06 2020-10-14 Synaffix B.V. Enediyne conjugates
EP3976112A1 (en) * 2019-06-03 2022-04-06 Synaffix B.V. Acetal-based cleavable linkers
GB2585102B (en) 2019-10-09 2021-06-30 Audio Inventions Ltd System for identification of a note played by a musical instrument
WO2025151608A1 (en) * 2024-01-10 2025-07-17 Systimmune, Inc. Connecting units for ligand-drug conjugates and methods of making and using thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139200A (ja) 1994-06-03 2005-06-02 Wyeth Holdings Corp メチルトリチオ抗腫瘍剤の複合体およびそれらの合成用中間体
WO2017172907A1 (en) 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
ES2061586T3 (es) * 1987-10-30 1994-12-16 American Cyanamid Co Analogos disulfuricos de agentes antitumorales ll-e33288.
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
WO2005009882A1 (en) * 2003-06-27 2005-02-03 Otis Elevator Company Absolute positioning system for elevators using dual encoders
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
JP6055404B2 (ja) * 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
WO2012007896A1 (en) 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Multifunctional antibody conjugates
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
AU2012335205A1 (en) 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
MX340090B (es) 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
US9453508B2 (en) 2013-02-25 2016-09-27 Asmo Co., Ltd. Electric oil pump and hydraulic pressure supply device
KR101614151B1 (ko) 2014-07-01 2016-04-22 한국화학연구원 흡입 독성 시험용 폐 모델 장치
ES2797754T3 (es) 2014-08-28 2020-12-03 Pfizer Enlazadores moduladores de la estabilidad para su uso con conjugados de fármaco y anticuerpo
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
WO2018069851A2 (en) 2016-10-11 2018-04-19 Sorrento Therapeutics, Inc. C-met antibody drug conjugate
MX2019008773A (es) * 2017-01-24 2019-09-18 Pfizer Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139200A (ja) 1994-06-03 2005-06-02 Wyeth Holdings Corp メチルトリチオ抗腫瘍剤の複合体およびそれらの合成用中間体
WO2017172907A1 (en) 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACS CHEMICAL BIOLOGY，2006年，Vol.1, No.8，pp.499-504
Bioconjugate Chem.，2008年，Vol.19，pp.358-361
CANCER RESEARCH，1993年，Vol.53，pp.3336-3342
J.Am.Chem.Soc.，1994年，Vol.116，pp.1225-1271
Ricart, A.，Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamici，Clin Cancer Res，2011年，17(20)，6417-6427

Also Published As

Publication number Publication date
AU2018211561B2 (en) 2020-04-30
EP3573995A1 (en) 2019-12-04
CA3051038C (en) 2022-07-26
TW201838632A (zh) 2018-11-01
US20240409573A1 (en) 2024-12-12
JP2018123122A (ja) 2018-08-09
CA3051038A1 (en) 2018-08-02
WO2018138591A1 (en) 2018-08-02
AU2018211561A1 (en) 2019-07-18
KR20190111086A (ko) 2019-10-01
IL268245A (en) 2019-09-26
BR112019015069A2 (pt) 2020-03-03
SG11201906414VA (en) 2019-08-27
CN110461860A (zh) 2019-11-15
RU2732568C1 (ru) 2020-09-21
MX2019008773A (es) 2019-09-18
TWI687221B (zh) 2020-03-11
US20190345186A1 (en) 2019-11-14
US11993625B2 (en) 2024-05-28

Similar Documents

Publication Publication Date Title
JP7078405B2 (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
CN106795203B (zh) 用于抗体药物缀合物的稳定性调节接头
KR20230145038A (ko) 생물활성 물질 접합체, 이의 제조방법 및 이의 용도
JP6612738B2 (ja) 抗ｈｅｒ２抗体−薬物コンジュゲート
CA2852860C (en) Cytotoxic peptides and antibody drug conjugates thereof
JP2025032192A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート
CA3233254A1 (en) Antibody, antibody-drug conjugate thereof and use thereof
CA2947484C (en) Anti-her2 antibody-maytansine conjugates and methods of use thereof
CA3168882A1 (en) Camptothecin derivatives and conjugates thereof
JP2024509099A (ja) 抗ｈｅｒ２抗体‐薬物コンジュゲートおよびその使用
JP6782250B2 (ja) Ｃｔｉファーマコフォアを含有する二官能性細胞毒性剤
CN106661123A (zh) 抗‑cd22抗体‑药物缀合物及其使用方法
JP2025516873A (ja) タンパク質分解剤クラスの生物学的活性化合物を含む抗体薬物複合体及びその調製方法並びに使用
JP2025537900A (ja) 縮合環式化合物及びその複合体並びに使用
CN119053607B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
WO2025015586A1 (en) Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof
HK40017839A (en) Calicheamicin derivatives and antibody drug conjugates thereof
JP2026502348A (ja) Ａｄｃコンジュゲーションのためのトポイソメラーゼｉ阻害剤のプロドラッグおよびその使用方法
WO2024193692A1 (zh) 连接子及其在配体药物偶联物中的应用
HK1245252A1 (zh) 包含cti药效团的双功能细胞毒性剂
HK1245252B (zh) 包含cti药效团的双功能细胞毒性剂
HK1237350A1 (en) Stability-modulating linkers for use with antibody drug conjugates
HK1204273B (en) Cytotoxic peptides and antibody drug conjugates thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220519

R150 Certificate of patent or registration of utility model

Ref document number: 7078405

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250